Phase 3 N=600 Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)
Human Papillomavirus
Primary: Geometric Mean Titers (GMTs) to HPV Types 16 and 18 — 6739.5; 6887.4; 1956.6; 1795.6 milli Merck Units/mL — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=63 Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy — 28.6 Percentage of…
N/A N=8 Tissue Biomarker for Pegvisomant Action
Acromegaly
Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL
Phase 2 N=60 Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Breast Cancer
Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…
Phase 4 N=14 Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Heart Transplant · Acute Graft Rejection · Chronic Graft Rejection
Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units
Phase 1 N=109 Safety Study of PLX4032 in Patients With Solid Tumors
Malignant Melanoma · Colorectal Carcinoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 on Day 1 - Dose Escalation: Original Formulation — 2.02; 3.28; 4.47; 4.23 ug*hr/mL
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 4 N=118 Dropless vs. Standard Drops Contralateral Eye Study
Cataract
Primary: Change From Baseline (Preoperative Exam) in Macular Thickness — 12.34; 10.96; 9.84 Microns
Phase 2 N=28 Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Adult Acute Lymphoblastic Leukemia in Remission · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Blastic Phase
Primary: Relapse Free Survival — 3 Participants
Phase 2 N=32 A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
Rhinitis, Allergic, Seasonal
Primary: Mean Messenger Ribonucleic Acid (mRNA) Concentrations as a Measure of Gene Expression — 2625.5; 2987.2; 3134.2; 3162.0 COPIES/50 nanogram (NG) — p=0.1351
Phase 4 N=77 Dexmedetomidine Versus Propofol in Vitreoretinal Surgery
Retinal Detachment
Primary: Adequate Sedation Via Bispectral Index Score (BIS)and University of Michigan Sedation Scale (UMSS) — 84.8; 88; .90; .94 units on a scale — p=0.04
Phase 2 N=96 Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
Mild Cognitive Impairment (MCI)
Primary: Brain Activity in the Dentate Gyrus / CA3 Subregion of the Hippocampus Measured With Blood Oxygenation Level Dependent (BOLD) Functional MRI — -0.1203; 0.4353; -0.2238…
Phase 3 N=300 Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation
Meningitis · Meningococcal Infection
Primary: Percentage of Participants Achieving Seroprotection Using a Serum Bactericidal Assay Human Complement With Antibody Titers ≥ 1:8 for Meningococcal Serogroups A, C, Y…
N/A N=360 Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico
Drug Abuse · HIV Risk Behavior
Primary: Alcohol, Smoking & Substance Involvement Screening Test (ASSIST) Score — 27.8; 29.6 units on a scale
Phase 4 N=82 T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010
Influenza
Primary: Number of Individual Twins Who Received Influenza Vaccine — 16; 14; 10; 20 Participants